Literature DB >> 14531046

Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?

Walter Pirker1.   

Abstract

During the past decade, dopamine transporter (DAT) imaging with single photon emission computerized tomography (SPECT) or positron emission tomography (PET) has evolved as an objective in vivo marker of nigrostriatal neuron loss in Parkinson's disease (PD). We investigate the relationship between striatal DAT binding, measured with [(123)I]beta-CIT SPECT, and parkinsonian motor handicap in a sample of 59 PD patients with minimal to severe disability, and review published cross-sectional studies on the correlation between DAT imaging and motor symptoms in PD. Earlier studies as well as the present results show a good correlation between overall striatal DAT binding and global measures of disease severity such as the Hoehn and Yahr scale, the total score on the Unified Parkinson's Disease Rating Scale (UPDRS), and UPDRS activities of daily living, with a progressive decline of DAT binding with increasing disability. A number of studies found a significant inverse correlation of striatal DAT binding with UPDRS motor score. Bradykinesia, posture, gait, and other midline symptoms, such as speech and facial expression, compared with rigidity, seem to be more closely related to striatal DAT binding. By contrast, neither the severity of parkinsonian rest nor of action tremor is related to the degree of dopaminergic denervation as measured by DAT imaging. Motor symptoms in the clinically less affected body side show a closer correlation with striatal DAT binding than do symptoms occurring in the dominantly affected body side. The correlation of putamen and caudate DAT binding with parkinsonian motor handicap seems to be similar. Although there have been limited comparative studies applying [(18)F]fluorodopa PET and DAT imaging in the same group of PD patients, available data suggest that putamen [(18)F]fluorodopa uptake, when compared with striatal DAT binding, may be more closely related to parkinsonian motor handicap. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531046     DOI: 10.1002/mds.10579

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  68 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

2.  Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease.

Authors:  Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  J Neurol       Date:  2011-04-22       Impact factor: 4.849

Review 3.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

4.  Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.

Authors:  Gaetano Barbagallo; Maria Eugenia Caligiuri; Gennarina Arabia; Andrea Cherubini; Angela Lupo; Rita Nisticò; Maria Salsone; Fabiana Novellino; Maurizio Morelli; Giuseppe Lucio Cascini; Domenico Galea; Aldo Quattrone
Journal:  Hum Brain Mapp       Date:  2017-06-20       Impact factor: 5.038

5.  Fatigue in levodopa-naive subjects with Parkinson disease.

Authors:  G Schifitto; J H Friedman; D Oakes; L Shulman; C L Comella; K Marek; S Fahn
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

6.  Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease.

Authors:  Bambi R Brewer; Sujata Pradhan; George Carvell; Anthony Delitto
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2009-10-30       Impact factor: 3.802

7.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

8.  Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.

Authors:  Yu Geng; Guo-hua Shi; Yun Jiang; Ling-xun Xu; Xing-yue Hu; Yu-quan Shao
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

9.  Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Anne Larsson; Lennart Johansson; Katrine Riklund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-01       Impact factor: 9.236

10.  Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Hiroto Kuwabara; Gregory M Constantine; Chester A Mathis; Robert Y Moore
Journal:  Neurosci Lett       Date:  2007-08-06       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.